Ingredia acquires Galactis Pharma
date:Mar 17, 2014
ent and anti-microbial qualities. Other peptides display a cholesterol-lowering action, offer immuno-modulating properties, or facilitate minerals transportation. Unlike pharmaceutical molecules, they generally have no side effects.

After further clinical investigation, Ingredia believes that the acquisition of Galactis Pharma will allow it to expand its portfolio of bioactive ingredients focused on health benefits and also enter the pain management market. Ingredia Nutritional, one of the comp
2/3 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/20 19:54